Physician profile
Robert L Dohlman
NPI 1154381069
$1,811.36
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $833 · 2020: $464 · 2021: $515.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $384.06 | 2019-2021 | |
| Astellas Pharma US INC | $254.85 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.26 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $156.13 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $149.15 | 2019-2021 | |
| Novo Nordisk INC | $139.59 | 2019-2021 | |
| Pfizer INC. | $116.15 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.04 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $54.81 | 2019-2020 | |
| Amgen INC. | $49.11 | 2019-2020 | |
| Medtronic Minimed, INC. | $41.53 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $26.24 | 2021 | |
| Collegium Pharmaceutical, INC. | $24.62 | 2019 | |
| Glaxosmithkline, LLC. | $24.27 | 2020 | |
| Amarin Pharma, INC. | $23.87 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $22.68 | 2019 | |
| Circassia INC. | $15.79 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $15.69 | 2021 | |
| Sunovion Pharmaceuticals INC. | $13.84 | 2021 | |
| Merck Sharp & Dohme LLC | $11.68 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dohlman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.